Found that ruxolitinib competitively inhibits the transportation purpose of ABCB1, and much more importantly, the expression of ABCB1 performs a job in pinpointing the efficacy of ruxolitinib in the cell line and in Key human T cells [ninety seven]. The effect of ruxolitinib on MDR mediated by ABC drug transporters https://ronp369djo9.activablog.com/profile